Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies.

McCaughan JA, O'Rourke DM, Courtney AE.

Am J Transplant. 2012 Apr;12(4):1046-51. doi: 10.1111/j.1600-6143.2011.03923.x. Epub 2012 Jan 10.

2.

Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.

Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT.

Pediatr Nephrol. 2014 Jul;29(7):1283-7. doi: 10.1007/s00467-013-2748-5. Epub 2014 Jan 26.

PMID:
24464478
3.

Eculizumab in dense-deposit disease after renal transplantation.

Sánchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, López-Trascasa M, Bedoya R, Rodríguez de Córdoba S, Ybot-González P.

Pediatr Nephrol. 2014 Oct;29(10):2055-9. doi: 10.1007/s00467-014-2839-y. Epub 2014 Jun 8.

PMID:
24908321
4.

Eculizumab for dense deposit disease and C3 glomerulonephritis.

Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB.

Clin J Am Soc Nephrol. 2012 May;7(5):748-56. doi: 10.2215/CJN.12901211. Epub 2012 Mar 8.

5.

Electron-dense deposit in renal transplant patients on eculizumab may be drug-derived.

Brealey JK, Cassidy J.

Ultrastruct Pathol. 2016;40(1):2-6. doi: 10.3109/01913123.2015.1090515. Epub 2015 Oct 29.

PMID:
26512451
6.

Eculizumab and recurrent C3 glomerulonephritis.

Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ.

Pediatr Nephrol. 2013 Oct;28(10):1975-81. doi: 10.1007/s00467-013-2503-y. Epub 2013 May 22.

7.

Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M.

Pediatr Nephrol. 2014 Jun;29(6):1107-11. doi: 10.1007/s00467-013-2711-5. Epub 2014 Jan 10.

PMID:
24408225
8.

Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.

Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.

Diagn Pathol. 2016 Oct 7;11(1):94.

9.

Eculizumab in Pediatric Dense Deposit Disease.

Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1773-82. doi: 10.2215/CJN.01360215. Epub 2015 Aug 27.

10.

Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.

Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC.

Pediatr Nephrol. 2016 Apr;31(4):683-7. doi: 10.1007/s00467-015-3306-0. Epub 2016 Jan 13.

PMID:
26759144
11.

Pathology after eculizumab in dense deposit disease and C3 GN.

Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D'Agati VD.

J Am Soc Nephrol. 2012 Jul;23(7):1229-37. doi: 10.1681/ASN.2011121186. Epub 2012 Jun 7.

12.

Eculizumab for the treatment of dense-deposit disease.

Vivarelli M, Pasini A, Emma F.

N Engl J Med. 2012 Mar 22;366(12):1163-5. doi: 10.1056/NEJMc1111953. No abstract available.

13.

Treatment of C3 glomerulopathy with complement blockers.

Vivarelli M, Emma F.

Semin Thromb Hemost. 2014 Jun;40(4):472-7. doi: 10.1055/s-0034-1375299. Epub 2014 May 5. Review.

PMID:
24799307
14.

Recurrent membranoproliferative glomerulonephritis after second renal graft treated with plasmapheresis and rituximab.

Pérez-Sáez MJ, Toledo K, Navarro MD, Lopez-Andreu M, Redondo MD, Ortega R, Pérez-Seoane C, Agüera ML, Rodríguez-Benot A, Aljama P.

Transplant Proc. 2011 Dec;43(10):4005-9. doi: 10.1016/j.transproceed.2011.09.079.

PMID:
22172889
15.

C3 glomerulopathy.

Servais A, Noël LH, Frémeaux-Bacchi V, Lesavre P.

Contrib Nephrol. 2013;181:185-93. doi: 10.1159/000348654. Epub 2013 May 8. Review.

PMID:
23689580
16.

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.

Transplant Proc. 2012 Dec;44(10):3037-40. doi: 10.1016/j.transproceed.2012.07.141.

PMID:
23195022
17.

Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome.

Andresdottir MB, Assmann KJ, Hoitsma AJ, Koene RA, Wetzels JF.

Nephrol Dial Transplant. 1999 Jul;14(7):1723-31.

PMID:
10435883
18.

Recurrent type III membranoproliferative glomerulonephritis after kidney transplantation.

Morales JM, Martinez MA, Muñoz de Bustillo E, Muñoz MA, Gota R, Usera G.

Transplantation. 1997 Apr 27;63(8):1186-8.

PMID:
9133484
19.

Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.

Nester CM, Brophy PD.

Curr Opin Pediatr. 2013 Apr;25(2):225-31. doi: 10.1097/MOP.0b013e32835df4a3. Review.

PMID:
23486421
20.

Early recurrence of dense deposit disease with marked endocapillary proliferation after renal transplantation.

Aita K, Ito S, Tanabe K, Toma H, Yamaguchi Y, Nagata M.

Pathol Int. 2006 Feb;56(2):101-9.

PMID:
16445823

Supplemental Content

Support Center